Quarry LP Buys 6,247 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

Quarry LP grew its stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS) by 2,469.2% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 6,500 shares of the company’s stock after purchasing an additional 6,247 shares during the period. Quarry LP’s holdings in NewAmsterdam Pharma were worth $108,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in NAMS. Banque Cantonale Vaudoise bought a new stake in NewAmsterdam Pharma during the 2nd quarter worth approximately $38,000. Bellevue Group AG bought a new stake in NewAmsterdam Pharma during the 3rd quarter worth approximately $128,000. Wolverine Asset Management LLC increased its holdings in NewAmsterdam Pharma by 117.7% during the 2nd quarter. Wolverine Asset Management LLC now owns 15,524 shares of the company’s stock worth $298,000 after purchasing an additional 8,394 shares in the last quarter. Sei Investments Co. increased its holdings in NewAmsterdam Pharma by 49.1% during the 2nd quarter. Sei Investments Co. now owns 24,561 shares of the company’s stock worth $472,000 after purchasing an additional 8,087 shares in the last quarter. Finally, Lisanti Capital Growth LLC bought a new stake in NewAmsterdam Pharma during the 3rd quarter worth approximately $700,000. 89.89% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on NAMS. Royal Bank of Canada restated an “outperform” rating and issued a $31.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Needham & Company LLC restated a “buy” rating and issued a $36.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday. Finally, Piper Sandler restated an “overweight” rating and issued a $37.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, NewAmsterdam Pharma presently has an average rating of “Buy” and a consensus price target of $33.80.

Insider Buying and Selling

In related news, major shareholder Nap B.V. Forgrowth sold 8,530 shares of the firm’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $25.02, for a total value of $213,420.60. Following the completion of the transaction, the insider now directly owns 11,812,033 shares of the company’s stock, valued at approximately $295,537,065.66. This trade represents a 0.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Louise Frederika Kooij sold 45,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $15.72, for a total transaction of $707,400.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 86,803 shares of company stock valued at $1,755,307. 19.50% of the stock is owned by insiders.

NewAmsterdam Pharma Stock Performance

Shares of NAMS opened at $18.35 on Friday. NewAmsterdam Pharma has a 1 year low of $8.90 and a 1 year high of $26.35. The stock’s fifty day moving average price is $19.87 and its two-hundred day moving average price is $18.55.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.